CN114746115A - 抗原结合蛋白构建体及其用途 - Google Patents

抗原结合蛋白构建体及其用途 Download PDF

Info

Publication number
CN114746115A
CN114746115A CN202080055954.6A CN202080055954A CN114746115A CN 114746115 A CN114746115 A CN 114746115A CN 202080055954 A CN202080055954 A CN 202080055954A CN 114746115 A CN114746115 A CN 114746115A
Authority
CN
China
Prior art keywords
seq
chain variable
variable domain
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055954.6A
Other languages
English (en)
Chinese (zh)
Inventor
A.J.尼科尔斯
B.P.费斯克
N.杰拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myth Therapy Co ltd
Original Assignee
Myth Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myth Therapy Co ltd filed Critical Myth Therapy Co ltd
Publication of CN114746115A publication Critical patent/CN114746115A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080055954.6A 2019-06-07 2020-06-05 抗原结合蛋白构建体及其用途 Pending CN114746115A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858932P 2019-06-07 2019-06-07
US62/858,932 2019-06-07
US201962888384P 2019-08-16 2019-08-16
US62/888,384 2019-08-16
PCT/US2020/036495 WO2020247873A1 (en) 2019-06-07 2020-06-05 Antigen-binding protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
CN114746115A true CN114746115A (zh) 2022-07-12

Family

ID=71899864

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055954.6A Pending CN114746115A (zh) 2019-06-07 2020-06-05 抗原结合蛋白构建体及其用途

Country Status (9)

Country Link
US (1) US20220313845A1 (https=)
EP (1) EP3980129A1 (https=)
JP (1) JP2022535452A (https=)
CN (1) CN114746115A (https=)
AU (1) AU2020289477A1 (https=)
CA (1) CA3142884A1 (https=)
IL (1) IL288685A (https=)
MX (1) MX2021015095A (https=)
WO (1) WO2020247873A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012523A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
US20230107901A1 (en) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Ｄｌｌ３抗原結合構築物
EP4577578A1 (en) 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
TW202602935A (zh) 2024-04-01 2026-01-16 美商米西克治療公司 抗原結合蛋白構築體及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844332A (zh) * 2010-03-11 2012-12-26 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
CN102918057A (zh) * 2010-03-30 2013-02-06 中外制药株式会社 促进抗原清除的与FcRn的亲和力得到改进的抗体
US20140363455A1 (en) * 2012-02-24 2014-12-11 Stem Centrx, Inc. Dll3 modulators and methods of use
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844332A (zh) * 2010-03-11 2012-12-26 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
CN102918057A (zh) * 2010-03-30 2013-02-06 中外制药株式会社 促进抗原清除的与FcRn的亲和力得到改进的抗体
US20140363455A1 (en) * 2012-02-24 2014-12-11 Stem Centrx, Inc. Dll3 modulators and methods of use
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BILAL H. LASHAR 等: "Rovalpituzumab Tesirine: A Novel DLL3‑Targeting Antibody–Drug Conjugate", DRUGS IN R&D, vol. 18, 19 September 2018 (2018-09-19), pages 255 - 258, XP055726162, DOI: 10.1007/s40268-018-0247-7 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012523A1 (zh) * 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途

Also Published As

Publication number Publication date
JP2022535452A (ja) 2022-08-08
CA3142884A1 (en) 2020-12-10
AU2020289477A1 (en) 2022-02-03
WO2020247873A1 (en) 2020-12-10
IL288685A (en) 2022-02-01
EP3980129A1 (en) 2022-04-13
MX2021015095A (es) 2022-03-22
US20220313845A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CN114746123A (zh) 抗原结合蛋白构建体及其用途
CN114746115A (zh) 抗原结合蛋白构建体及其用途
US12331125B2 (en) Anti-cMet antibody-drug conjugates and uses thereof
US20220306751A1 (en) Antigen-binding protein constructs and uses thereof
US20220298260A1 (en) Antigen-binding protein constructs and uses thereof
KR20250012620A (ko) Ph 의존적으로 결합하는 ptk7-결합 단백질 및 이의 용도
US20240158493A1 (en) Antigen-binding protein constructs and antibodies and uses thereof
JP7818509B2 (ja) 抗原結合タンパク質構築物およびその使用
KR20260007365A (ko) Trop2-결합 단백질 및 이의 용도
HK40114906A (en) Anti-met antibodies and uses thereof
HK40102142A (en) Anti-met antibodies and uses thereof
HK40102142B (en) Anti-met antibodies and uses thereof
CA3142886A1 (en) Antigen-binding protein constructs and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination